IRVING, Texas, February 16, 2021 / PRNewswire / – Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on delivering the promise of precision medicine, today announced that the Dana-Farber Cancer Institute (Dana- Farber) has joined the Caris Precision Oncology Alliance ™. (The Alliance / POA). The Alliance is a collaborative network of leading cancer centers working together to advance comprehensive cancer profiling and set standards for molecular testing in oncology through research focused on predictive and prognostic markers that improve clinical outcomes cancer patients. At Dana-Farber, it will operate out of the Lank Center for Genitourinary Oncology.
Since 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today, while developing the cures of tomorrow through cutting-edge research. Dana-Farber is the primary educational affiliate of Harvard Medical School, a clinical partner of Brigham & Women’s Hospital for adult cancer care and Boston Children’s Hospital for pediatric cancer and blood disorders and care. As a founding member of the Dana-Farber / Harvard Cancer Center, a Comprehensive Cancer Center appointed by the National Cancer Institute and a member of the National Comprehensive Cancer Network, Dana-Farber is one of the world’s leading cancer centers and is consistently the First ranked cancer hospital in New England and one of the nation’s top cancer centers.
“Dana-Farber has a long history of leading the development of cancer treatments and guidelines,” said Chadi Nabhan, MD, MBA, FACP, President of the Caris Precision Oncology Alliance. “The POA is excited to work with some of the best physicians and oncology specialists to advance our collective mission to advance precision medicine and research for the betterment of all cancer patients. “
“Our team is committed to advancing precision oncology for patients. We look forward to working with Caris as part of the Precision Oncology Alliance to leverage big data to inform biomarker-driven trials and improve patient care, ”said Himisha Beltran, MD, director of translational research in medical oncology at Dana-Farber and Associate Professor of Medicine at the Lank Center for Genitouriary Oncology at Dana-Farber.
The Caris Precision Oncology Alliance includes more than 45 cancer centers and academic institutions. These institutions have quick access to Caris’ extensive database and artificial intelligence platform to set evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, Caris seeks to provide this network with the ability to prioritize treatment options and determine what clinical trial opportunities may benefit their patients. . POA members are also able to fit into a growing portfolio of Biopharma sponsored biomarker directed trials. Additionally, as a member of the POA, institutions have access to Caris CODEai ™, the industry’s most comprehensive data solution with cancer treatment information and clinical outcome data for over 215,000 patients. covering over 1,000,000 data points per patient.
“Collaborating with influential members like Dana-Farber aligns with POA’s vision to create the best research network that focuses on precision oncology to identify predictive and prognostic markers to improve outcomes and outcomes. clinical care of cancer patients worldwide, ”said Brian J. Brille, vice-president of Caris Life Sciences.
To learn more about the Precision Oncology Alliance, visit the Caris website at CarisLifeSciences.com/collaboration.
About Caris Life Sciences
Caris Life Sciences® is a leading innovator in molecular science and artificial intelligence, focused on realizing the promise of precision medicine through quality and innovation. The company’s advanced molecular profiling suite of offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more accurate and personalized treatment decisions. MI Exome™ whole exome sequencing with 22,000 DNA genes and MI Transcriptome™ Complete transcriptome sequencing with 22,000 RNA genes as well as analysis of cancer-related pathogens, bacteria, viruses and fungi performed on each patient provides the most comprehensive and clinically comprehensive DNA and RNA profiling relevant available in the market.
Caris is also advancing precision medicine with Caris Artificial Intelligence, by combining its market-leading service offering, Caris Molecular Intelligence®, with its proprietary artificial intelligence analysis engine, DEAN™, to analyze the whole exome, the whole transcriptome and the whole cancer proteome. This information, coupled with mature clinical results on thousands of patients, provides unparalleled molecular solutions for patients, physicians, payers and biopharmaceutical organizations.
Caris Pharmatech is changing paradigm and streamlining the clinical trial process by helping biopharmaceutical companies access research-ready oncology sites for clinical trials. With more than 350 research sites within the Caris Pharmatech Just-In-Time (JIT) oncology network, biopharmaceutical companies can identify and recruit more patients, faster. Caris Pharmatech’s just-in-time clinical trial solutions focus on rapid site activation and patient recruitment to streamline the drug development process. By implementing Caris’ Just-in-Time Trial Matching System, Caris will automatically match patients to clinical trials and sites can be activated and eligible to enroll patients within one week.
Based at Irving, Texas, Caris Life Sciences has offices in Phoenix, Denver, New York, and Basel, Switzerland. Caris provides services across the United States, Europe, Asia and other international markets. For more information, please visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).
About the Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers for cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific research, clinical care, education, community engagement and advocacy. We provide the latest cancer treatments for adults through Dana-Farber / Brigham and Women’s Cancer Center and for children through Dana-Farber Center / Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital in the country with a top 10 American News and World Report Best ranking of cancer hospitals in adult and pediatric care
As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating discovery results into new treatments for patients locally and globally, delivering over 1,100 clinical trials.
Caris Life Sciences press contact:
Dana-Farber Cancer Institute media contact:
Media Relations Manager
SOURCE Caris Life Sciences